Skip to main content

ORF73/HHV8 Antibody (LN53) [Alexa Fluor™ Plus 555]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-22767AFP555

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-22767AFP555
Forumulation
Catalog #

Key Product Details

Species Reactivity

Virus

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoassay

Label

Alexa Fluor Plus 555

Antibody Source

Monoclonal Rat IgG2C Clone # LN53

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Recombinant protein corresponding to the latent nuclear antigen-1 molecule of HHV8.

Localization

Nuclear

Specificity

This antibody reacts with ORF-73 of human Herpes virus 8 (HHV8). HHV8 is the likely etiological agent of Kaposi's sarcoma (KS). HHV8 encodes a latent nuclear antigen (LNA) which is the product of the viral gene orf 73. LNA is capable of forming a complex with retinoblastoma susceptibility gene product which may be related to its oncogenic activity.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2C

Applications for ORF73/HHV8 Antibody (LN53) [Alexa Fluor™ Plus 555]

Application
Recommended Usage

Immunoassay

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: ORF73 HHV8

HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.

Long Name

ORF73 of Human Herpesvirus 8

Alternate Names

HHV8GK18_gp81, LANA1

Gene Symbol

HHV8GK18_gp81

Additional ORF73 HHV8 Products

Product Documents for ORF73/HHV8 Antibody (LN53) [Alexa Fluor™ Plus 555]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for ORF73/HHV8 Antibody (LN53) [Alexa Fluor™ Plus 555]



This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...